Bayer launches Medrad Mark 7 Arterion Injection System

Bayer HealthCare’s Radiology and Interventional unit has launched the new Mark 7 Arterion® Injection System, the latest in the Medrad Mark series of angiographic injectors.

“The Arterion injection system was designed with efficiency in mind,” said Diane Watson, Head of Interventional Fluid Delivery at Bayer HealthCare’s Radiology and Interventional unit. “It’s light and maneuverable with features that are meant to simplify the delivery of contrast media used in angiograms to determine the extent of arterial blockage.”

The first Medrad Mark injector was introduced for use in angiograms more than 40 years ago. The Arterion injection system joins the company’s portfolio of interventional devices used to restore blood flow – providing physicians a complimentary line of products to diagnose and treat cardiovascular disease.

“The Mark 7 Arterion system's user interface facilitates the setting up and performing of contrast injections," said Robyn Reising, of Decatur Memorial Hospital where the very first Arterion system was installed in the U.S. "The front-load system shall streamline the pre- and post-procedure activities and the clear syringe allows us to monitor the purging of air."

A History of Leadership in Power Injection

The Mark 7 Arterion Injector extends more than 40 years of category leadership in providing power injectors to deliver contrast media used in angiography, computed tomography (CT) and magnetic resonance (MR) labs. In 1964, the first Medrad injector – called the Heilman-Wholey Injector – was the first flow-controlled angiographic injector commercialized in the U.S. The Arterion is the seventh in the Mark series for angiography.

Operating today as Bayer HealthCare’s Radiology and Interventional business, the company remains a market leader in power injection.

About Bayer HealthCare

The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 17.2 billion (2011), is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare’s aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 55,700 employees (Dec 31, 2011) and is represented in more than 100 countries. Find more information at www.bayerhealthcare.com.

Back to top

Bayer launches Medrad Mark 7 Arterion Injection System

Bayer HealthCare’s Radiology and Interventional unit has launched the new Mark 7 Arterion® Injection System, the latest in the Medrad Mark series of angiographic injectors.

“The Arterion injection system was designed with efficiency in mind,” said Diane Watson, Head of Interventional Fluid Delivery at Bayer HealthCare’s Radiology and Interventional unit. “It’s light and maneuverable with features that are meant to simplify the delivery of contrast media used in angiograms to determine the extent of arterial blockage.”

The first Medrad Mark injector was introduced for use in angiograms more than 40 years ago. The Arterion injection system joins the company’s portfolio of interventional devices used to restore blood flow – providing physicians a complimentary line of products to diagnose and treat cardiovascular disease.

“The Mark 7 Arterion system's user interface facilitates the setting up and performing of contrast injections," said Robyn Reising, of Decatur Memorial Hospital where the very first Arterion system was installed in the U.S. "The front-load system shall streamline the pre- and post-procedure activities and the clear syringe allows us to monitor the purging of air."

A History of Leadership in Power Injection

The Mark 7 Arterion Injector extends more than 40 years of category leadership in providing power injectors to deliver contrast media used in angiography, computed tomography (CT) and magnetic resonance (MR) labs. In 1964, the first Medrad injector – called the Heilman-Wholey Injector – was the first flow-controlled angiographic injector commercialized in the U.S. The Arterion is the seventh in the Mark series for angiography.

Operating today as Bayer HealthCare’s Radiology and Interventional business, the company remains a market leader in power injection.

About Bayer HealthCare

The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 17.2 billion (2011), is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare’s aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 55,700 employees (Dec 31, 2011) and is represented in more than 100 countries. Find more information at www.bayerhealthcare.com.

Back to top